[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100564561":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":55,"collaborators":20,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trial Group","EXPERIMENTAL","All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.\n\n(1) Tumor bed (CTVtb): It was delineated based on the tumor extent shown in laryngoscopy, enhanced CT\u002FMRI, or PET CT before induction therapy49. For patients with significant anatomical changes due to tumor regression, the CTVtb was adjusted, taking into account the patient's anatomy after induction chemotherapy and the initial state of the tumor; if a cavity appeared due to tumor regression, it was adjusted according to natural anatomical boundaries.(2) High-risk clinical target volume (CTV1): CTVtb plus a 5-10mm margin, with a prescribed dose of at least 60Gy in 30 fractions.\n\n(3) Low-risk clinical target volume (CTV2): CTV1 plus a 5-10mm margin. For hypo",[13],"Radiation: Head and Neck Cancers",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Head and Neck Cancers","All patients received intensity-modulated conformal radiotherapy (IMRT). To ensure study quality, all IMRT plans were reviewed by the research team at Sun Yat-sen University Cancer Center. The delineation principles for the radiotherapy target volume of the primary tumor bed and normal tissues followed the consensus guidelines.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Liu-Wei Tang","The Ethics Committee of the Center for Cancer Prevention and Treatment, Sun Yat-sen University","STUDY_DIRECTOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Chun-Yan Chen","CONTACT","020-87342926","86","chenchuny@sysucc.org.cn",{"name":34,"role":29,"phone":30,"phoneExt":31,"email":35},"Ya-Ni Zhang","zhangyn1@sysucc.org.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":45,"coordinates":46},"Point",[47,48],113.25,23.11667,{"lat":48,"lon":47},[51,53],{"name":52,"role":29,"phone":30,"phoneExt":20,"email":32},"Chun-Yan Chen, Prof.",{"name":54,"role":29,"phone":30,"phoneExt":20,"email":35},"Ya-Ni Zhang, Dr.",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Chen Chunyan","Clinical Professor","100564561","reduction-of-postoperative-radiotherapy-in-head-and-neck-squamous-cell-carcinoma-100564561",false,"NCT06630780","Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma","A Prospective Phase II Clinical Trial on the Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma","REPORT-HNSCC","Inclusion Criteria:\n\n* Preoperative pathologically confirmed initial treatment of head and neck squamous cell carcinoma\n* Receive neoadjuvant chemotherapy combined with PD-1 monoclonal antibody immunotherapy, and meet one of the following conditions: Preoperative clinical stage was T3-T4 or N2-N3 (AJCC 8th edition). Patients with oral cancer\u002Foropharyngeal cancer had positive lymph nodes in the IV\u002FV region with imaging diagnosis or biopsy confirmation before surgery. HPV\u002F P16-positive oropharyngeal cancer patients with clinical lymph node invasion (ENE), one positive cervical lymph node \\> 3cm or multiple positive cervical lymph nodes before surgery\n* The pathology of at least one cervical lymph node was determined by pCR；\n* Karnofsky's physical status score ≥70 points；\n* Age: 18 \\~ 70 years old；\n* Laboratory examination results within 1 week before enrollment met the following conditions: neutrophils (ANC) ≥1.5×109\u002FL, platelets (PLT) ≥ 75×109\u002FL\n* Patients participate voluntarily and sign informed consent forms.\n\nExclusion Criteria:\n\n* Previous head and neck radiation treatment\n* Severe complications；\n* Pregnant or lactating women\n* Who were deemed unsuitable for inclusion by the researchers.","ALL","18 Years","70 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"NA","To explore the control rate and quality of life of participants with late head and neck squamous cell carcinoma who have obtained postoperative pCR after cervical lymph node surgery with neoadjuvant chemotherapy combined with immunotherapy, and the cervical lymph node removal prophylactic irradiation ENI in the low-risk area.",[78],"Head and Neck Squamous Cell Carcinoma (HNSCC)",[80,81,82,83,84],"HNSCC","Post-radical surgery","Adjuvant Radiotherapy","Radiation dose reduction","Quality of life","2026-04-24",{"date":87,"type":88},"2026-04-30","ACTUAL",{"date":90,"type":88},"2024-09-26",{"date":92,"type":72},"2029-12-31",{"name":5,"class":6},1]